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Abstract: In recent years there has been an immense development of new targeted anti-cancer drugs. For practic-
ing precision medicine, a sensitive method imaging for non-invasive, assessment of early treatment response and 
for assisting in developing new drugs is warranted. Magnetic Resonance Spectroscopy (MRS) is a potent technique 
for non-invasive in vivo investigation of tissue chemistry and cellular metabolism. Hyperpolarization by Dynamic 
Nuclear Polarization (DNP) is capable of creating solutions of molecules with polarized nuclear spins in a range of 
biological molecules and has enabled the real-time investigation of in vivo metabolism. The development of this new 
method has been demonstrated to enhance the nuclear polarization more than 10,000-fold, thereby significantly in-
creasing the sensitivity of the MRS with a spatial resolution to the millimeters and a temporal resolution at the sub-
second range. Furthermore, the method enables measuring kinetics of conversion of substrates into cell metabo-
lites and can be integrated with anatomical proton magnetic resonance imaging (MRI). Many nuclei and substrates 
have been hyperpolarized using the DNP method. Currently, the most widely used compound is 13C-pyruvate due to 
favoring technicalities. Intravenous injection of the hyperpolarized 13C-pyruvate results in appearance of 13C-lactate, 
13C-alanine and 13C-bicarbonate resonance peaks depending on the tissue, disease and the metabolic state probed. 
In cancer, the lactate level is increased due to increased glycolysis. The use of DNP enhanced 13C-pyruvate has 
in preclinical studies shown to be a sensitive method for detecting cancer and for assessment of early treatment 
response in a variety of cancers. Recently, a first-in-man 31-patient study was conducted with the primary objec-
tive to assess the safety of hyperpolarized 13C-pyruvate in healthy subjects and prostate cancer patients. The study 
showed an elevated 13C-lactate/13C-pyruvate ratio in regions of biopsy-proven prostate cancer compared to non-
cancerous tissue. However, more studies are needed in order to establish use of hyperpolarized 13C MRS imaging 
of cancer.
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Introduction
Increasingly, therapies are tailored either th- 
rough targeting specific abnormalities, e.g. 
genetic mutations, or through early response 
monitoring. Sensitive methods for non-invasive 
in vivo imaging assessment of early treatment 
response as well as assisting in developing new 
drugs are warranted. Positron Emission Tomo- 
graphy (PET) imaging with fluorodeoxyglucose 
(FDG) has been established as a clinical tool in 
molecular imaging. FDG is a glucose analog 
labeled with the positron-emitting isotope 18F. It 
is transported across the cell membrane by 
glucose transporters (GLUTs), phosphorylated 
by hexokinase, trapped in the cell and accumu-
lates in proportion to local metabolism. 
Increased 18F-FDG uptake is then detected 
using a PET scanner [1]. 18F-FDG uptake can be 
measured using standardized uptake value 
(SUV), which is a quantitative measure of radio-
activity concentration in PET images normal-
ized to injected dose and body weight, 18F-FDG 
SUV thus measures tumor metabolic activity. 
However, this standard has certain limitations 
and can be affected by factors such as blood 
glucose level in the patient [2]. Conventional 
computed tomography (CT) is a sensitive ana-
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tomical scanning technique in tumor imaging, 
however it lacks physiological information. 
Introduction of new CT techniques (dual energy 
CT and CT perfusion imaging with iodine con-
trast agents) together with recent advances in 
hardware has improved spatial and temporal 
resolution, and physiological information is now 
obtainable from CT datasets. Nevertheless, 
when evaluating treatment response, consecu-
tive acquisitions are usually performed yielding 
a substantial radiation burden; therefore non-
ionizing methods should be considered as an 
alternative. Diffusion Weighted Magnetic Reso- 
nance Imaging (DW-MRI) is non-ionizing and 
measures the movement of proton nuclei, pri-
marily from water, and thereby demonstrates 
tissue cellularity and integrity of cell mem-
branes. Diffusion based MRI has proven to be 
useful for staging and predicting prognosis of 
cancer patients. However, diffusion based MRI 
is only sensitive to structural information and 
lacks metabolic information [3].
MR spectroscopy
Magnetic Resonance Spectroscopy (MRS) 
imaging is like MRI based on the principle of 
nuclear magnetic resonance (NMR). MRS is a 
potent technique for non-invasive in vivo inves-
tigation of tissue chemistry. MRS has been 
widely applied in biochemistry research for the 
analysis of basic organic compounds and pro-
vides information about e.g. tissue metabo-
lites. Conventional proton MRI uses magnetic 
gradients to create controlled perturbations of 
the magnetic field, thus creating anatomical 
images. MRS likewise codes the spatial dimen-
sions, but in addition, utilizes the miniscule dif-
ferences in resonance frequency of the various 
nuclei, depending on the molecular structure, 
creating an accurate illustration of metabolic 
lites can be quantified. The method is primarily 
used in brain and prostate cancer and spectra 
associated with tumor tissue are distinguished 
from those associated with normal tissue by 
the characteristic increase in the resonance 
peak of choline corresponding to increased cell 
membrane density [4, 5]. There are several limi-
tations to this technique, with consequential 
decrease of temporal resolution to the minute 
scale and of spatial resolution to 1 cm3 depend-
ing on the nucleus detected and of the mag-
netic field strength [6, 7]. Moreover, spectro-
scopic images of tissue metabolites lack 
dynamic information about metabolic fluxes 
[8].
Dynamic nuclear hyperpolarization
A more sensitive method that allows real time 
imaging of the dynamics of the metabolism is 
therefore necessary. Hyperpolarization in the 
context of NMR refers to the process of relocat-
ing the nuclei temporarily into a redistribution 
of energy levels [9]. The hyperpolarization pro-
cess can be accomplished by a number of tech-
niques; 1) optical pumping, which is primarily in 
use for noble gases as 3He and 129Xe in lung 
perfusion imaging [10], 2) PHIP (para hydrogen-
induced polarization) which suffers from the 
limited number of metabolic substrates that 
can be hyperpolarized [11, 12] or 3) dynamic 
nuclear hyperpolarization (DNP). A more exten-
sive description of the two former methods can 
be found elsewhere and is beyond the scope of 
this paper.
Ardenkjaer-Larsen et al. first described hyper-
polarization with DNP and was established on 
DNP in the solid state. The method is based on 
the development of a dissolution technique 
Table 1. Table with MR biologically interesting 
nuclides and demonstrating, that only the nuclei 
of phosphor (31P) and hydrogen (1H) exist in high 
enough concentrations to be used for routine clini-
cal evaluation [70]
Nuclide Abundance in tissue
MR-detect. 
isotope
Abundance 
of isotope
Abundance 
in tissue
H 63% 1H 99.99% 63%
C 12% 13C 1.1% 0.13%
N 0.58 % 15N 0.37% 0.0021%
O 24% 17O 0.038% 0.0091%
P 0.22% 31P 100% 0.22%
chemistry in situ. In theory, many biochemi-
cally relevant nuclides, such as hydrogen 
(1H), carbon (13C), nitrogen (15N), fluorine (19F), 
sodium (23Na) and phosphor (31P) possess a 
magnetic moment and can be used for MRS. 
However, only the nuclei of phosphor (31P) 
and hydrogen (1H) exist in high enough con-
centrations to be used for routine clinical 
evaluation, see Table 1. Depending on the 
chemical structure of the molecule, the 
nuclei responsible for the NMR signal is 
exposed to a slightly different magnetic envi-
ronment, hence resonating at a slightly dif-
ferent frequency. This way various metabo-
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that preserves the nuclear polarization during 
the transition from solid to liquid state. The 
method is capable of creating solutions of mol-
ecules with polarized nuclear spins in various 
molecules and has enabled the real-time inves-
tigation of in vivo metabolism [13, 14]. The pro-
cedure consists of polarization transfer from 
electrons to nuclei in solids by microwave irra-
diation. The solution to be polarized typically 
contains 13C-enriched substrates; a free stable 
radical is dissolved in a glass-forming solvent 
and then positioned into a high magnetic field 
(e.g. 3 T). The free radical provides unpaired 
electrons and the glassing material optimize 
the efficiency of microwave energy transfer. 
The compound is brought to very low tempera-
ture (≈1 K) and irradiated. After the polarization 
transfer, the microwaves are turned off, and the 
metabolite is warmed rapidly to room tempera-
grated with anatomic proton MRI [14]. One limi-
tation, however, is a relatively short half-life 
(10-30 s in vivo) of the hyperpolarized metabo-
lites. Therefore, the solution requires rapid 
transfer into the patient and the imaging 
sequence must be efficient and accomplished 
within 2-3 minutes and the metabolites must 
be metabolized and transferred across the cell 
membrane very rapidly [14]. 
Many nuclei have been hyperpolarized using 
the DNP method. Currently, the most widely 
used metabolite is 13C-pyruvate due to the opti-
mal gyromagnetic ratio, the relatively long 
relaxation time and finally the possibility of 
incorporating 13C into biological relevant metab-
olites [16, 17]. Intravenous injection of the 
hyperpolarized 13C-pyruvate results in an 
increase of 13C-lactate, 13C-alanine and 13C- 
Figure 1. A key metabolic fingerprint in cancer cells is the switch to glycolysis 
with production of lactate even in the presence of sufficient oxygen (repro-
duced with permission from ref [68]).
ture with substantial reten-
tion of the polarization that 
was present in the frozen 
solid state. It is then quickly 
transferred and injected into 
the specimen or animal for 
MRI acquisition. The nuclear 
spin polarization is propor-
tional to gamma (γ) and B0/T 
where γ is the nucleus spe-
cific gyromagnetic ratio con-
stant, B0 is the applied mag-
netic field and T is tempera-
ture. With this method, a liq-
uid state polarization of up to 
64% has been achieved [15]. 
The time for the polarization 
to build up to maximum level 
is about one hour.
The use of this new method 
has enhanced the nuclear po- 
larization more than 10,000-
fold. It has resulted in a sig-
nificantly increased sensitivi-
ty of the MRS and increased 
the spatial resolution to the 
millimeter scale and the tem-
poral resolution to the sub 
second range. Furthermore, 
these advances makes it 
possible to measure the 
kinetics of the conversion of 
the metabolite into other cell 
metabolites and can be inte-
DNP 13C-pyruvate in cancer
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bicarbonate resonance peaks depending on 
the tissue, disease and the metabolic state 
probed. In cancer, 13C-lactate is increased due 
to increased glycolysis. Numerous studies have 
shown that glycolysis and production of lactate 
and alanine is increased in tumor cells com-
pared to normal cells even when oxygen is suf-
ficient a phenomenon known as Warburg effect 
[18], as shown in Figure 1.
Use of hyperpolarized 13C-pyruvate in cancer
Detecting tumor response to treatment
Currently treatment response is assessed by 
imaging measurement to monitor anatomical 
tumor reductions in accordance with the latest 
guidelines of the “Response Evaluation Criteria 
In Solid Tumors” (RECIST). Here, partial 
response to treatment is defined as “at least a 
30% decrease in the sum of the longest 
diameter of target lesions, taking as reference 
the baseline sum longest diameter” [19]. 
However these anatomic changes defining 
partial response may take weeks to develop in 
cells after treatment can mask the decreased 
uptake by the dying cancer cells and correlates 
with the number of metabolically active viable 
cells, regardless of whether they are tumoral or 
non-tumoral in nature. Sustained high 18F-FDG 
uptake can occur in a tumor mass after 
administration of chemotherapy due to 
infiltrating macrophages [26]. Lastly, PET 
exposes the patient to significant radiation 
burden and can only be repeated a limited 
number of times.
Proton based MRS has the potential to provide 
routine assessment of cancer treatment. 
However, it is still a relatively novel technology 
and more work is required to validate the bio-
markers that MRS can detect [27]. In an ortho-
topic animal model of glioma, it was investigat-
ed whether changes in 1H MRS metabolites 
could render reliable biomarkers for an early 
response to suberoylanilide hydroxamic acid 
(SAHA) treatment which blocks histone de-
acetylation activity and results in the accumu-
lation of acetylated histones and proteins, such 
as transcription factors essential for expres-
Figure 2. Color maps representing 13C-lactate and 13C-pyruvate peak intensi-
ties obtained from 13C chemical-shift images in the same mouse before and 
after treatment with etoposide. The images were acquired between 20 and 
25 s after intravenous injection of 0.2 ml 75 mM hyperpolarized 13C-pyruvate 
and 20 h after injection of the mice with 67 mg/kg etoposide. Tumor margins 
are indicated by the white lines. Reprinted with kind permission from Nature 
Medicine [30].
tumors and in some cases 
not develop at all or even de- 
monstrate growth due to 
tumor stasis after treatment 
[20, 21]. In these situations 
ineffective treatment or even 
harmful treatment can be 
given. Consequently, 18F-FDG- 
PET imaging has or is under 
investigation for therapy res- 
ponse assessment in many 
tumors. Quantitative estima- 
tion of 18F-FDG uptake by 
SUV in tumor has demon- 
strated a distinct reduction of 
glucose to predict response 
of treatment, despite the fact 
that tumor increased in size 
[22]. However, 18F-FDG-PET 
lacks sensitivity to certain 
tumor types, due to low 18F-
FDG uptake (e.g. prostate 
cancer) [23], high uptake in 
surrounding tissue (brain 
cancers) [24] or specificity 
due to 18F-FDG uptake in 
infected or inflamed tissue 
[25]. In addition, high 18F-FDG 
uptake of infiltrating immune 
DNP 13C-pyruvate in cancer
552 Am J Nucl Med Mol Imaging 2015;5(5):548-560
sion of genes necessary to induce cell differen-
tiation [28]. Wei et al. demonstrated a decrease 
in the concentration of lactate in tumors of 
treated rats. These results indicate that SAHA 
inhibits tumor growth and induces normal brain 
tissue-like metabolism in brain tumors [29]. 
One of the earliest studies using hyperpolar-
ized 13C-pyruvate in treatment response in can-
cer used lymphoma lesion in mice treated with 
topoisomirase inhibitor (Etoposide). Etoposide 
induces loss of NAD(H) and decrease in LDH 
activity and consequently apoptosis with dem-
onstration of decreased flux in hyperpolarized 
13C-pyruvate and 13C-lactate [30], see Figure 2. 
This flux is inhibited within 24 hours of treat-
ment. Witney et al. compared 18F-FDG-PET and 
hyperpolarized 13C-pyruvate for detecting tumor 
response to treatment of murine lymphoma 
and demonstrated that the timing of response 
varied. The decreased 18F-FDG uptake was pre-
ceded by the decrease in flux of 13C metabolite 
between pyruvate and lactate, however with 
equal relative reductions in both 18F-FDG and 
hyperpolarized 13C-pyruvate/13C-lactate. This 
suggests that the most important advantage of 
hyperpolarized MRI may be in response assess-
ment in cancers where 18F-FDG-PET is insensi-
tive [31]. Decreased hyperpolarized 13C-lactate 
was also shown in a cell line of human breast 
adenocarcinoma treated with another topoi-
somirase inhibitor (doxorubicin) where the level 
of hyperpolarized 13C-lactate production was 
decreased before any detectable change in 
tumor size reflecting DNA [32]. The phosphati-
dylinositol 3-kinase (PI3K) pathway has been 
found to have key regulatory roles in many cel-
lular processes, including cell survival, prolifer-
ation, glucose metabolism and cell differentia-
tion. Several anti cancer therapeutic drugs tar-
geting the pathway are in clinical trials [33]. 
Traditional imaging methods such as CT and 
MRI are inadequate in monitoring early treat-
ment response due to tumor stasis rather than 
shrinkage associated with PI3K inhibition [34]. 
Hyperpolarized 13C-pyruvate was used in mice 
with subcutaneously implanted glioblastoma 
xenografts detecting the effect of PI3K inhibi-
tion and produced a decrease of hyperpolar-
ized 13C-lactate. This finding was then con-
firmed in mice with breast cancer cells and 
associated with reduction in LDH activity of 
expression and hypoxia-inducible factor-1α pro-
teins (HIF-1α) [35]. This was also shown in a 
more clinically relevant model involving inva-
sive orthotopic (intracranial) glioblastoma 
xenografts in rats treated with Everolimus, an 
mTOR inhibitor that is part of the PI3K pathway 
[36]. The same mouse model was also treated 
with the most frequently used chemothera- 
peutic in treating glioblastoma, Temozlomide, 
an alkylating agent that works by damaging 
DNA. It was demonstrated that the ratio of 
hyperpolarized 13C-pyruvate to 13C-lactate was 
increased in the treatment group [37]. Cell sig-
nalling through the PI3K pathway can be inhib-
ited by various receptor tyrosine kinase inhibi-
tors (RTK) (Imatinib) and was associated with 
receptors for the stem cell factor (c-KIT) and 
platelet-derived growth factor (PDGFR) [38]. In 
a prostate cancer model inhibition of PDGFR 
with Imatinib reduced the flux of hyperpolarized 
13C-lactate by lowering the expression of LDH 
itself, which was mediated, by reduced expres-
sion of their transcriptional factors HIF-1α and 
c-MYC [39]. Vascular disrupting agents are che-
motherapeutics that selectively targets endo-
thelial cell and leads to tumor cell necrosis and 
is not triggering tumor shrinkage [40]. Vascular 
function has been measured using dynamic 
contrast agent-enhanced MRI and 15O-H2O-
PET, however the necessity of a wide variety of 
kinetic models and an onsite cyclotron and has 
limited its use in clinical practice. In a murine 
lymphoma model, the rate of flux of hyperpolar-
ized 13C between pyruvate and lactate was 
decreased by 34% within 6 and 24 hours of 
treatment with the vascular disrupting agent 
combrestatin-A4-phosphate (CA4P). A simulta-
neously change on dynamic contrast agent-
enhanced MRI after 6 hours was demonstrat-
ed, which was normal after 24 hours. DWI MR 
showed no change on the ADC (apparent diffu-
sion coefficient) of tumor after 6 hours of treat-
ment, although a decrease after 24 hours was 
observed and therefore it was concluded that 
hyperpolarized 13C-pyruvate might provide a 
more sensitive indicator in vascular disrupting 
drugs than the traditionally used MR modalities 
[41]. The same group also demonstrated that 
hyperpolarized 13C MRS can detect the early 
effects of anti-angiogenic therapy (bevacizum-
ab, Avastin) in 2 colorectal cancer xenograft 
models (LoVo and HT29), which are known to 
display differential response to VEGF (vascular 
endothelial growth factor) blockade [42].
Other categories of treatment against cancer 
have also been examined. In the TRAMP model, 
DNP 13C-pyruvate in cancer
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Table 2. Overview of studies investigating treatment of response of cancer with hyperpolarized 13C-pyruvate
Therapy Host Cancer type Cancer cell line Tumor  inoculation
13C-pyruvate/ 
lactate response Other imaging modalities Reference
Etoposide Mice Lymphoma EL-4 (moue) S.c. Decreased 13C-lactate  [30]
Etoposide Mice Lymphoma EL-4 (mouse) S.c. Decreased 13C-lactate 18F-FDG-PET: Decreased SUV. [31]
Doxyrubicin Cell media Breast adenocarcinoma MDA-MB-231 (Human) Decreased 13C-lactate  [32]
LY294002 Cell media Glioblastoma GS-2 (human) Decreased 13C-lactate  [35]
Everolimus Cell media Breast adenocarcinoma MDA-MB-231 (human) Decreased 13C-lactate  [35]
Everolimus Mice Glioblastoma GS-2 (human) S.c. Decreased 13C-lactate  [35]
Everolimus Mice Glioblastoma GS-2 (human) I.c. Decreased 13C-lactate MRI (T2, T1GD): No response. [36]
Imatinib Mice Prostate adenocarcinoma PC-3MM2 (human) Tibia Decreased 13C-lactate MRI (DCE): Significant decease in vascular permeability. [39]
Imatinib/ Paclitaxel Mice Prostate adenocarcinoma PC-3MM2 (human) Tibia Decreased 13C-lactate MRI (DCE): Significant decease in vascular permeability. [39]
Combretastatin-A4-phosphate Mice Lymphoma EL-4 (mouse) S.c. Decreased 13C-lactate MRI (DCE): Significant suppression of uptake at 6 h 
after treatment, returning to above pretreatment values 
at 24 h. DWI: 6 h after treatment no change, 24 h after 
treatment increase in ADC.
[41]
Bevacizumab (Avastin) Mice Colorectal adenocarcinoma LoVo (human) S.c. Decreased 13C-lactate MRI (DCE): Antivascular effects were observed at 24 
h after the first dose of, but began to recover after the 
second dose (72 hours. DWI: No change in ADC).
[42]
Bevacizumab (Avastin) Mice Colorectal adenocarcinoma HT29 (human) S.c. Increased 13C-lactate MRI (DCE): No antivascular effects. DWI: Decrease in 
ADC after 72 h of treatment.
[42]
Androgen deprivation Mice Prostate Adenocarcinoma TRAMP (orthotopic) Decreased 13C-lactate [43]
Radiotherapy Rats Glioma C6 (rat) I.c. Decreased 13C-lactate  [44]
S.c.: subcutaneous. I.c.: intracranial. DCE: dynamic contrast enhancement.
DNP 13C-pyruvate in cancer
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anti-androgenic therapy demonstrated that 
hyperpolarized 13C-pyruvate correlated with dis-
ease progression and increased in untreated 
animals [43]. In addition, the pre-treatment 
13C-lactate to 13C-pyruvate ratio was a predictor 
of treatment outcome [2]. Day et al. investigat-
ed a rat model of gliobastoma in treatment of 
radiotherapy and 13C hyperpolarization. It was 
demonstrated that a response could be detect-
ed after radiotherapy through decreased 13C 
labeling of tumor lactate. Response could be 
detected even though an increase in tumor vol-
ume was demonstrated [44]. This study shows 
that it may be possible to distinguish between 
true progression and pseudo progression due 
to tumor stasis and could be used to guide sub-
sequent treatment using hyperpolarized 13C- 
pyruvate. An overview of treatment response 
studies is given in Table 2.
Application in brain tumor imaging
18F-FDG-PET studies have shown increased 
rate of glucose uptake, increased expression 
of GLUT transporters in numerous cancers and 
a correlation of glucose uptake and accumu-
lation of lactate with the aggressiveness and 
prognosis [45]. The application of 18F-FDG-PET 
in clinical neuro-oncology is limited by the high 
background uptake of normal gray matter and 
low specificity [24]. Therefore other investiga-
tions are warranted in brain tumor imaging. 
Several studies have demonstrated that in-
creased lactate production is found in human 
glioma [46] and rat glioma models [47]. Proton 
MRS (1H MRS) has been one tool to character-
ize lactate production of brain tumors and el-
evated lactate has been associated with poor 
survival in patients with glioblastoma multi-
forme [48]. However the interpretation of MRS 
is difficult in this highly heterogeneous tumor, 
since increased lactate level is dependent upon 
increased glycolysis and rate of lactate produc-
tion and clearance. Furthermore, because of 
the complexity in separating the lactate peaks 
from cystic and necrotic regions. Consequently 
an alternative technique for assessing the tu-
mor metabolism is necessary. Park et al. com-
pared the in-vivo metabolism in malignant 
glioma and normal rat brain with two different 
human glioma xenografts (U-251 MG and U-87) 
and demonstrated the feasibility of hyperpolar-
ized 13C-pyruvate in characterizing brain tumors 
from normal brain and between the different 
glioma cell lines [37, 49].
Application in prostate cancer imaging
Prostate cancer is the second leading cause of 
cancer deaths in men. Most men diagnosed at 
a very early stage will die with prostate cancer 
but not from the disease [50]. Distinguishing 
lethal from clinically indolent disease is a para-
mount interest in prostate cancer manage-
ment. So far prostate cancer is diagnosed by 
histopathologic samples from the gland by ran-
dom transrectal biopsies. Gleason grading on 
histopathological examination is the best prog-
nostic indicator in prostate cancer to date; 
though, grading on biopsies may not correlate 
with the prostatectomy specimen because of 
sampling errors, interobserver variation, and 
morphologically identical prostate cancer can 
behave differently [51]. The transgenic adeno-
carcinoma of mouse prostate (TRAMP) model 
mimics that of human prostate cancer. The 
TRAMP model develops progressive, heteroge-
neous and multifocal disease and spontaneous 
prostatic neoplasia which progresses to carci-
noma and metastasis in lymph nodes, lungs 
and less frequently liver, adrenal glands and 
bones [52]. The first study with hyperpolarized 
13C-pyruvate was applied in the TRAMP model 
by Chen et al. and presented the feasibility of 
detecting rapid cellular conversion of 13C- 
pyruvate to 13C-lactate in tumor and allowed 
the acquisition of 3D MRS in approximately 10 
s with a spatial resolution of 0.135 cm3 [53]. 
Serial data from Albers et al. demonstrated 
that it was possible to differentiate and mea-
sure the histological grade on the basis of 
13C-lactate levels in normal prostate, low-grade 
tumors and high-grade tumors. 13C-lactate lev-
els and histological grade had a correlation 
coefficient of 0.95. Additionally, lymph node 
metastasis had significantly elevated levels of 
13C-lactate as well [54]. Lupo et al. confirmed 
this and demonstrated that variations in 
13C-lactate signal intensities were apparent for 
different stages of disease development, with 
correlation between elevated 13C-lactate levels 
and advanced disease. The intensity of the 
13C-lactate level varied spatially within the 
tumor consistent with the known heterogeneity 
of the disease [55]. To evaluate the use of 
hyperpolarized 13C-pyruvate on a larger scale, 
Nelson et al. demonstrated the feasibility in 
healthy dogs because of the resemblance in 
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anatomy and size of the prostate gland to that 
of the human. Coil geometry, data acquisition 
parameters and radiofrequency pulses were 
developed and provided a realistic test of the 
methodology. The observed 13C-lactate to 
13C-pyruvate ratio was significantly lower than 
previously seen in kidneys and tumors of small-
er animals but was still increased in the healthy 
dog prostate [56].
A phase 1 “Ascending-dose study to assess the 
safety and tolerability and imaging potential of 
hyperpolarized pyruvate (13C) injection in sub-
jects with prostate cancer” was undertaken at 
the University of California, San Francisco. This 
first-in-man 31-patients study was conducted 
with the primary objective to assess the safety 
of hyperpolarized 13C-pyruvate in healthy men 
and prostate cancer patients, and confirmed 
the safety of the agent. In addition it showed 
elevated 13C-lactate/13C-pyruvate ratio in re- 
gions of biopsy-proven prostate cancer com-
pared to non-cancerous tissue of the prostate 
[57].
Application in breast cancer
The metabolite flux depends upon delivery of 
pyruvate via the vasculature, on the rate of 
pyruvate transport across the plasma cell 
membrane and on the concentration of lactate 
dehydrogenase (LDH) and its substrates. 
Consequently, understanding the changes in 
lactate levels will require interpreting the rela-
tive significance of these steps in establishing 
the kinetics of metabolite exchange [14]. In 
human breast cancer cells, it was shown that 
the flux of hyperpolarized 13C-pyruvate assum-
ing simple Michaelis-Menten kinetics was 
transferred to the cell as determined by the 
monocarboxylic acid transporter-1 (MCT). MCT 
is a member of a family of trans-membrane pro-
teins, which introduces pyruvate into the glyco-
lytic pathway. Conversely the addition of a 
Figure 3. View of HyperPET and description of the Warburg effect. Increased 18F-FDG uptake is a composite quan-
tity of numerous hallmarks of cancer, e.g. metabolic changes, cell proliferation and hypoxia. While measured 13C-
pyruvate to 13C-lactate switch probably expresses the Warburg per se. Modified from [68].
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MCT1 inhibitor (Quercetin) markedly reduced 
the apparent rate of 13C-pyruvate to 13C-lactate 
conversion and stressed out that the rate of 
metabolism of hyperpolarized pyruvate does 
not reflect the activity of LDH, but rather the 
activity of the MCT transporters in a breast can-
cer population [58]. However as shown by 
Witney et al. in a murine lymphoma cell line, the 
control of metabolite flux is probably shared 
between the membrane transporter and LDH 
[14].
Application in liver cancer
The incidence of liver cancer is continuously 
increasing and is usually diagnosed at a late 
stage [59]. Thus a sensitive non-invasive mark-
er of disease with regard to prognosis and 
treatment of response is warranted. Yen et al. 
developed a single voxel based MRS sequence 
that was able to measure T2 relaxation times of 
hyperpolarized 13C-metabolites in vivo. They 
demonstrated that hyperpolarized 13C-alanine 
and 13C-lactate level were elevated in a rat 
model of hepatocellular carcinoma compared 
to normal liver tissue [60]. This was confirmed 
by Darpolor et al. who demonstrated that the 
conversion of hyperpolarized 13C-pyruvate to 
13C-alanine and 13C-lactate was associated 
with elevation of the enzymes of LDH and ala-
nine transaminase (ALT) [61]. This suggests 
that the elevated levels of hyperpolarized 
13C-lactate and 13C-alanine in hepatocellelular 
carcimona can be dependable upon the up-
regulation of LDH and ALT. Hu et al. used a 
switchable transgenic mouse model with over-
expression of the proto-oncogene MYC in the 
liver, giving rise to tumors that have features of 
human hepatocellular carcinoma and hepato-
blastoma. Interestingly, conversion of 13C- 
pyruvate to 13C-alanine was predominant in 
very early stages of pre-tumor tissue, prior to 
any observable morphologic or histological 
changes. The increase of hyperpolarized 
13C-alanine level highlights the potential of 
13C-alanine as an early biomarker in liver can-
cer [62]. Continuously, a pulse sequence meth-
odology was implemented to improve spatial 
resolution (to as high as 0.034 cm3) and 
achieve up to a factor of 7.53 in acceleration 
for 3D spectroscopic imaging in the same 
transgenic mouse model of liver cancer. In clini-
cal applications, this new pulse sequence could 
be used to cover a larger field of view [63] and 
therefore MRS could visualize larger volumes of 
tumors in one sequence. Menzel et al. demon-
strated that hyperpolarized 13C-pyruvate corre-
lated with 18F-FDG-PET in a rat model with 
hepatocellular carcinoma in most of the ani-
mals. Intratumoral heterogeneities due to 
necrosis could be identified in the 13C metabol-
ic and 18F-FDG images [64].
Applications in other cancers
The first study using hyperpolarized 13C-pyruvate 
in cancer used P22 tumor tissue, a highly 
malignant rat sarcoma. It was demonstrated 
that all implanted tumors showed significantly 
higher lactate content than the normal tissues 
and indicated that non-invasive quantification 
of localized Warburg effect may be possible 
[65]. Renal cell carcinoma is a very heteroge-
neous cancer with varying aggressiveness and 
prognosis. Differentiation between malignant 
and benign small renal tumors is difficult with 
conventional imaging, like ultrasound, CT and 
PET [66]. Keshari et al. demonstrated that 
hyperpolarized MRS of 13C-pyruvate to 
13C-lactate ratio could be used to distinguish 
normal renal cells from renal cell carcinoma. In 
addition, they used the technique to show that 
metastatic renal cell carcinoma had a signifi-
cantly higher 13C-lactate/13C-pyruvate ratio 
compared to the cells derived from localized 
renal cell carcinoma and that the differences 
were mediated by the MCT4 transporter [67].
Conclusion and perspective
The use of hyperpolarized 13C-pyruvate for 
characterizing tumor metabolism has been 
demonstrated pre-clinically in an array of can-
cers. Recently the application was also shown 
clinically in prostate cancer. The information 
obtained is overlapping with that of 18F-FDG-
PET and the question is therefore if there is a 
role for clinical routine use of 13C-pyruvate in 
cancer. We have demonstrated, for the first 
time, the feasibility of a new imaging concept 
combining hyperpolarized 13C-pyruvate MRSI 
and 18F-FDG-PET imaging [68]. A concept we 
have named hyperPET [69]. In a canine cancer 
patient with a biopsy verified sarcoma we found 
clearly increased 13C-lactate production, which 
also corresponded to high 18F-FDG uptake on 
PET. This is in agreement with the fact that gly-
colysis and production of lactate are increased 
in tumor cells compared to normal cells [68], 
see Figures 3 and 4. To the degree that 13C- 
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pyruvate and 18F-FDG-PET leads to similar infor-
mation there is no doubt that 18F-FDG is the 
method of choice: It is less costly, available in 
most hospitals, and renders whole body evalu-
ation of metabolism. However, in some cancer 
types, e.g. prostate cancer 18F-FDG-PET is not 
useful and here 13C-pyruvate may represent an 
attractive alternative. Also in children, the con-
cern of radiation burden could make 13C- 
pyruvate the method of choice. With the emer-
gence of hybrid PET/MR systems it is possible 
to conjoin 18F-FDG-PET and 13C-pyruvate MRS, 
which may be of increased value. With regard to 
early response monitoring in cancer treatment, 
the possibility exist that 13C-pyruvate can detect 
such effect earlier and with higher sensitivity 
than other methods. Also this can only be 
answered through comparative PET and MR 
studies.
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